NeuroPace RNS System real-world outcomes: 7-year prospective registry shows continuous improvement pattern
Summary
A 7-year prospective registry of 324 patients with NeuroPace RNS System for drug-resistant focal epilepsy demonstrated a continuous improvement pattern with median seizure reduction increasing from 44% at 1 year to 75% at 7 years. Thirty-five percent of patients achieved ≥90% seizure reduction at 7 years. The improving long-term outcome pattern — unique to responsive neurostimulation versus stable conventional DBS outcomes — was confirmed across all hippocampal and neocortical target sites.
Why it matters
Seven years of continuous improvement — seizure reduction growing from 44% to 75% — validates the long-term neuroplasticity hypothesis for RNS. This dataset also directly supports NeuroPace's case for moving RNS earlier in epilepsy treatment: if outcomes improve over years of stimulation, starting earlier would mean patients receive maximum benefit earlier in their disease course.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial